Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Fig. 4

The 16-gene signature discriminates in the validation dataset the 154 patients who experienced grade 0–1 from the 56 patients who experienced grade 2–4 diarrhea with an AUC 0.785 (95% CI 0.723, 0.838; p < 0.0001). a Accuracy of patient classification of as a function of diarrhea grade using the 16 gene signature. b Dot diagram depicting the 16-gene signature results in discovery dataset patients (N = 150) experiencing grade 0–1 diarrhea (designated as 0) versus grade 2–4 diarrhea patients (designated as 1) with a 0.15 cut-off. c Receiver operating characteristic curve plotting sensitivity of the 16-gene signature on the y axis and 100-specificity on the x axis in validation dataset patients

Back to article page